• 1
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 2
    Hirsch FR, Varella-Garcia M, Franklin WA, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002; 86: 14491456.
  • 3
    Kern JA, Schwartz DA, Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990; 50: 51845187.
  • 4
    Diez M, Pollan M, Maestro M, et al. Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue. Br J Cancer. 1997; 75: 684689.
  • 5
    Hsieh CC, Chow KC, Fahn HJ, et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg. 1998; 66: 11591163.
  • 6
    Shi D, He G, Cao S, et al. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog. 1992; 5: 213218.
  • 7
    Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001; 7: 18501855.
  • 8
    Tan D, Deeb G, Wang J, et al. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol. 2003; 12: 201211.
  • 9
    Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997; 15: 28582865.
  • 10
    Pfeiffer P, Clausen PP, Andersen K, et al. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer. 1996; 74: 8691.
  • 11
    Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med. 1998; 157: 10931097.
  • 12
    MacKinnon M, Kerr KM, King G, et al. p53, c-erbB-2, and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. Eur J Cardiothorac Surg. 1997; 11: 838842.
  • 13
    Tsai C, Chang K, Perng R, et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst. 1993; 85: 897901.
  • 14
    Tsai C, Yu D, Chang K, et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst. 1995; 87: 682684.
  • 15
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783792.
  • 16
    Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol. 2000; 27 2125;: discussion 92–100.
  • 17
    Lara PN Jr., Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004; 5: 231236.
  • 18
    Langer CJ, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004; 22: 11801187. Epub 2004 Feb 23.
  • 19
    Zinner RG, Glisson BS, Fossella FV, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 2004; 44: 99110.
  • 20
    Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 2004; 15: 1927.
  • 21
    Pellegrini C, Falleni M, Marchetti A, et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res. 2003; 9: 36453652.
  • 22
    Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004; 431: 525526.
  • 23
    Arteaga CL, Khuri F, Krystal G, et al. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin Oncol. 2002; 29: 1526.
  • 24
    Moasser M, Basso A, Averbuch S, et al. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001; 71847188.